drugset

drugset / Trial / NCT07096843

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT07096843 ↗

Phase 2 Recruiting 45 enrolled Climb Bio, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Timeline

Start: 2025-08-25
Primary completion: 2027-10
Completion: 2027-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Budoprutug	Monoclonal antibody	—	Intravenous

Indications